Drug Trial Radar · NCT01292460
Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
Last checked: Nov 19, 2026Latest source record: Mar 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
600
Planned (sponsor's estimate)
Start
Feb 2011
Primary completion
Sep 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Santen OyIndustry
- Sponsor type
- Industry
- First posted
- Feb 9, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed tafluprost-timolol combination to those of tafluprost and timolol alone. This study will enroll patients who have ocular hypertension or glaucoma and who are using timolol or prostaglandin. The study medication period is 6 months, but the primary evaluation of efficacy is done at 3 months.
Conditions
- Ocular Hypertension
- Open-angle Glaucoma
Interventions
Timolol/ FDC/ Placebo/ TafluprostDrug
Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00). Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the average diurnal Intraocular Pressure (IOP) at 3 monthsTime frame: At 3 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Eye clinic, University Hospital of Kuopio
Kuopio, Finland
Eye Clinic, University Hospital of Oulu
Oulu, Finland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.